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Novel chemical probes for the investigation
of nonribosomal peptide assembly†
Y. T. Candace Ho,a Daniel J. Leng,a Francesca Ghiringhelli,ab Ina Wilkening,a
Dexter P. Bushell,a Otto Ko¨stner,ac Elena Riva,a Judith Havemann,a
Daniele Passarella b and Manuela Tosin *a
Chemical probes were devised and evaluated for the capture of
biosynthetic intermediates involved in the bio-assembly of the
nonribosomal peptide echinomycin. Putative intermediate peptide
species were isolated and characterised, providing fresh insights
into pathway substrate flexibility and paving the way for novel
chemoenzymatic approaches towards unnatural peptides.
Peptidic molecules are the most abundant and versatile chemical
entities in nature: from proteins to small peptides, they display
countless architectures and exert key roles in almost every known
biological process. In the context of secondary metabolism,
peptide natural products comprise a vast array of bioactive
molecules that regulate interspecies communication and organism
survival. Peptide natural products can be either biosynthesised by
the ribosome (and hence known as ribosomal peptides, RiPPs)
or by the multifunctional enzymes nonribosomal peptide
synthetases (NRPSs).1
Amongst NRPs we encounter potent anticancer agents, such
as bleomycin, and antibiotics of last resort, such as vancomycin
and teicoplanin.2 In NRP biosynthesis aminoacyl units, anchored
as thioesters to peptidyl carrier proteins (PCPs) via the phospho-
pantetheine cofactor,3 are joined together through peptide bond
formation by condensation (C) domains (Fig. 1A). Similarly to
polyketide and fatty acid synthases (PKSs and FASs, respectively),
NRPSs generate growing enzyme-bound biosynthetic intermedi-
ates which are variably processed and ultimately converted to the
final products. The ability of NRPSs to process proteinogenic and
non-proteinogenic amino acids, fatty acids and a-hydroxy acids,
linking them in diﬀerent ways, give rise to astonishing diversity
in product structure and bioactivity. Key domains utilised in
peptide elaboration throughout assembly include methyl-
transferases, epimerases4 and heterocyclases, whereas tailoring
enzymes acting in post-NRPS processes comprise oxidases,5
halogenases6 and glycosyltransferases.7
In NRPS assembly, adenylation (A) domains act as ‘gate-keepers’
by selecting specific amino acids and activating them as adenosine
monophosphate (AMP) esters for their loading onto the phospho-
pantetheine cofactors of PCPs.8 C domains catalyse peptide bond
formation and present two distinct substrate-binding sites: a ‘donor
site’ for upstream PCP-bound amino acids, and an ‘acceptor site’ for
downstream PCP-bound amino acids; the free amino groups of the
latter act as nucleophiles towards the thioestermoiety of PCP-bound
upstream substrates to generate extended PCP-bound intermediates
(Fig. 1A), which are subsequently transferred to other sites for
further extension and elaboration.9 Eventually peptide chain assem-
bly is terminated, mostly by thioesterase (TE) domains promoting
peptide hydrolysis or cyclisation;10 additional mechanisms of
peptide chain termination and release include reduction of the
final thioester bond to an aldehyde or an alcohol by R domains.11
Fig. 1 (A) General mechanism of nonribosomal peptide assembly;
(B) proposed capture of peptide biosynthetic intermediates (2) via newly
devised chain termination probes (1) based on nonhydrolysable analogues
(X = NH) of PCP-bound amino acids. PCP = peptidyl carrier protein;
C = condensation domain; d = aminoacyl donor site; a = aminoacyl acceptor
site. R3 = variable alkyl moiety; R4 = variable amino acid side chain.
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As PKSs and FASs, NRPSs can be modular or iterative enzymes: the
former comprise multiple sets of domains (modules), with each
module catalysing at least one round of peptide chain extension and
a direct correspondence between protein predicted function and
product in most cases.12 Conversely, iterative synthases are con-
stituted by modules that are used more than once to catalyse
peptide chain growth and processing,13 hence the nature of their
products is not fully predictable.
The engineering of NRPS enzymes and pathways remains amajor
synthetic biology focus in view of novel peptide production.14–17
Despite the much-improved ability to engineer NRPSs, many details
on peptide assembly catalysed by these enzymes remain unknown,
limiting our ability to fully exploit existing NRPSs and to design
de novo enzymes of improved versatility and efficiency.
Over the years mechanistic insights on NRP assembly have been
gathered from isotopic labelling of aminoacyl building blocks,18
genetic manipulation of in vivo biosynthetic pathways (e.g. by
domain inactivation, deletion, etc.),19 NRPS activity reconstitution
in vitro,11a,20 mass spectrometry of metabolites and enzyme-bound
precursors,20c,21 and enzyme conformational/structural elucidation.22
Nonetheless we still lack a comprehensive and dynamic picture of
how NRPS machineries work in vivo as a whole in processing
substrates and successfully conveying intermediates to the end of
a biosynthetic process. A major hurdle in gathering this information
is given by the covalent tethering of NRP intermediates to their
biosynthetic enzymes throughout peptide assembly.
In the past few years our group has developed ‘chain termination’
probes for the investigation of polyketide biosynthesis: nonhydrolys-
able small molecule mimics of malonate building blocks recruited in
polyketide formation were devised to interfere in the key decarbox-
ylative Claisen condensation step leading to polyketide chain assem-
bly, thereby ‘capturing’ transient biosynthetic intermediates for
characterisation.23–26 These tools have proved successful for inter-
mediate isolation and characterisation of intermediate species from
modular23b,24,26 and iterative PKS enzymes,23a,25 gathering in vitro and
in vivo key information on the timing and themechanism of catalytic
events otherwise inaccessible, and unveiling novel opportunities for
natural product diversification.24c
Given the similarity between PKSs and NRPSs in processing
carrier protein-bound species, we reasoned that chemical probes
mimicking PCP-bound amino acids could be developed to interfere
in NRPS-catalysed peptide bond formation and capture intermediate
peptide species for further characterisation. Hence we prepared a
library of putative probes (3–17, Table 1) for the investigation of
echinomycin assembly in the soil bacterium S. lasaliensis. Echinomycin
(18, Fig. 2) is an antitumor antibiotic that acts as DNA bis-intercalator
due to its two-fold symmetry and quinoxaline-derived moieties. It is
biosynthesised by an iterative NRPS that assembles two identical
peptide chains from 2-quinoxaline carboxylic acid, L-serine, alanine,
cysteine and valine (Fig. 2): a terminal thioesterase domain catalyses
depsipeptide formation and lactonisation, followed post-NRPS oxida-
tive processing.27
The probes devised by us wereN-acyl cysteamine derivatives28 that
mimic PCP-bound aminoacyl moieties and feature nonhydrolysable
amide bonds in place of cleavable thioester bonds (1, X = NH, Fig. 1)
in order to prevent substrate re-loading onto NRPSs. We reasoned
that, once within NRPS active sites, these molecules should be
recognised as acceptor substrates by C domains and hence compete
with PCP-bound aminoacyl units for peptide bond formation,
ultimately resulting in the oﬀ-loading and capture of prema-
turely truncated peptides (2, Fig. 1B).
We initially preparedN-acetyl substrates based on cognate amino-
acyl moieties such as the alanine derivative 3 (Table 1) via standard
peptide synthesis procedures (ESI†). These molecules were adminis-
tered in variable concentrations to liquid and solid cultures of
S. lasaliensis ACP12 (S970A), an engineered strain of S. lasaliensis
NRRL 3382R incapable of producing the polyketide lasalocid A24a but
still capable of generating the nonribosomal peptide echinomycin in
relevant levels. Preliminary LC-HRMSn analysis of organic extracts of
microbial fermentations showed that the probes were present and
hydrolytically stable but no evidence of feasible intermediates (data
not shown). We reasoned that perhaps the hydrophilicity of peptide
intermediates could hamper their isolation via organic extraction.
Therefore we prepared probes of variable N-acyl chain length
(R3, Fig. 1 and Table 1) in order to increase their hydrophobicity and
cellular uptake. Besides, variable side chain moieties (variable R4,
Fig. 1) and amino acid scaﬀold motifs (e.g. a versus b-amino acids,
Table 1) were also included in the probe structure in order to assess
the substrate flexibility of the echinomycin NRPS machinery in vivo.
Table 1 Chemical probes prepared for the capture of peptide biosyn-
thetic intermediates in echinomycin bio-assembly (see Fig. 2)
Probe structure R3
Compound
number Captured species
CH3 3 n.d.
(CH2)2CH3 4 Dipeptide
b
(CH2)5CH3 5 Di-, tri-, tetrapeptide
b
(CH2)8CH3 6
c n.d.
(CH2)2CH3 7 Di-, tripeptide
b
(CH2)5CH3 8 Di-, tri-, tetrapeptide
b
(CH2)5CH3 9 Di-,
a tripeptideb
(CH2)2CH3 10 Dipeptide
a, tri-, tetra-,
pentapeptidesb
(CH2)5CH3 11 Dipeptide
a, tri-,
tetrapeptidesb
(CH2)8CH3 12
c n.d.
(CH2)2CH3 13 Dipeptide
a, tri-,
tetrapeptideb
(CH2)5CH3 14 Dipeptide
a,
tripeptideb
(CH2)8CH3 15 n.d.
(CH2)5CH3 16 Dipeptide
b
(CH2)5CH3 17 n.d.
a Major species. b Detected in minor amounts (see ESI). c Displaying
cytotoxicity above 1 mM.
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An overview of echinomycin putative intermediates captured from
S. lasaliensis ACP12 (S970A) via the newly devised chemical probes is
given in Table 1 and Fig. 2. A whole range of captured species
spanning from dipeptides to pentapeptides (whose putative struc-
tures are represented in Fig. 2) were isolated and characterised by
HR-MSn: these were identified as putative echinomycin intermediates
by MSn fragment peaks (obtained from amide cleavages) featuring
quinoxaline 2-carboxylic acid and other amino acid constituents of
echinomycin in the expected sequence/order (as shown in Fig. 2C
and in the ESI†). The putative species were absent in control samples
and substantially varied in amount and distribution according to the
probe utilised (ESI†).
Besides the expected species captured from probes based on
cognate substrates, additional species deriving from non-cognate
pseudo-substrates were detected (Table 1, Fig. 2 and the ESI†). For
instance, dipeptides allegedly deriving from the oﬀ-loading of the
starter quinoxaline 2-carboxylic acid were detected in significant
amounts from experiments utilising non-cognate glycine (Fig. 2B)
and b-alanine probes (Fig. 30S, ESI†) as well as the cognate serine
substrates (Fig. 17S, ESI†). Further advanced species (from tri- to
pentapeptides) were most eﬃciently detected and characterised in
extracts deriving from bacterial fermentations in the presence of
N-butyroyl and N-heptanoyl glycine (Fig. 21S–23S, 26S and 27S, ESI†),
alanine (Fig. 8S, ESI†), b-alanine (Fig. 31S and 32S, ESI†), and valine
probes (Fig. 2C). No intermediate species were captured utilising the
aromatic L-phenylalanine pseudo-substrate 17.
Aminoacyl N-acetylcysteamine (SNAc) thioesters28 have been often
utilised to reconstitute the activity of C domains in vitro and have
shown that C acceptor sites generally exhibit strong stereoselectivity
(L- versus D-), together with some selectivity towards the side chain of
amino acids. Variants of nonribosomal peptides resulting from the
incorporation of diﬀerent amino acids can be observed in vivo,9b and
this has been utilised for precursor-directed biosynthesis purposes.14
However, to the best of our knowledge, the current study constitutes
the first report of in vivo probing of nonribosomal peptide assembly
utilising aminoacyl N-acetylcysteamine substrate mimics.
The overall results gathered by us seem to indicate that: (1) the
echinomycin biosynthetic machinery possesses some flexibility
towards the processing of ‘unnatural’ substrates in the correspon-
dence of specific C domains, possibly due to flexible pseudo-
substrate positioning at the enzyme active site during peptide bond
formation9d and/or probe bioavailability in vivo: this seems particu-
larly true for Gly and b-alanine substrates, which lack side-chain
stereochemistry and steric hindrance; (2) dipeptides accumulate
preferentially in comparison tomore advanced intermediate species
(see ESI† figures): this suggests that the first condensation step
might be the slowest amongst all those taking place throughout
echinomycin peptide chain assembly.
A more in-depth assessment and dissection of these in vivo
findings will require separate in vitro experiments with recombi-
nant C domains, as well as the development of advanced
analytical tools29 capable of deconvoluting the acquired LC-MS
data in a quantitative fashion. Nonetheless the preliminary
experiments herein reported demonstrate that the in vivo
profiling of NRP assembly via chain termination probes is now
possible, with important implications for future biosynthetic
pathway engineering. The screening of natural product bio-
assembly can indeed provide not only preliminary information
on substrate recognition but also insights on the kinetics of
natural product assembly,26 constituting the rational for
Fig. 2 (A) Overview of echinomycin nonribosomal peptide assembly and in vivo capture of putative biosynthetic intermediates via chemical probes 3–17
(note: the general intermediate structures apply to all substrates with the exception of b-alanine-based probes 13–15, ESI†); (B) extracted ion
chromatogram of a dipeptide resulting from the capture of quinoxaline 2-carboxylic acid by probe 11 (observed MS2 fragments indicated, ESI†); (C) HR-
MS2 analyses of a tetrapeptide intermediate resulting from the capture of an enzyme-bound tripeptide by probe 8. The stereochemistry of captured
intermediates is yet to be established.
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devising novel chemoenzymatic approaches towards unnatural
peptide production.
In summary, we have herein gathered a first direct view of
substrate processing for an iterative NRPS in vivo through the use
of newly devised nonhydrolysable ‘chain termination’ probes.
Further applications of these tools for the investigation of nonribo-
somal peptide pathways will be reported in due course.
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